Merck & Co., US58933Y1055

Merck & Co. stock heads into the open after a 1.6% gain

Published on 09/18/2026 at 07:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 17, 2026, Merck & Co. stock finished at USD 147.17 on the NYSE, up 1.56 percent for the day as it continued to trade near recent highs. The move outpaced the broader market, with investors watching oncology pipeline and dividend support.

Photorealistic wide-angle view of a modern oncology research laboratory. A scientist in white lab coat examines cancer cell slides under a fluorescence microscope. Amber glass vials with pharmaceutical compounds line the stainless steel bench. Biosafety c
Merck US58933Y1055 Onkologie-Labor: Wissenschaftler am Mikroskop analysiert Krebszellen, mehrere Wirkstoff-Vials stehen auf der Werkbank, Illustration mit AI erstellt.

Merck & Co. stock closed at USD 147.17 on the New York Stock Exchange on September 17, 2026, gaining 1.56 percent from the prior session in USD terms. Per exchange data, the shares moved between roughly USD 144 and USD 148 during the day, leaving the price near the upper end of Merck & Co.'s recent trading range and above the broader US market performance.

September 17, 2026 in numbers

Merck & Co., Inc. (ISIN US58933Y1055, NYSE: MRK) ended the most recent completed trading day at USD 147.17 on the NYSE, up 1.56 percent from the previous close, according to a wrap from Zacks. The same report noted that Merck & Co. outperformed the broader market in that session, with the S&P 500 index advancing less than the stock's 1.56 percent move on September 17, 2026, underscoring the relative strength in the shares.

Recent commentary has highlighted how Merck & Co.'s valuation and dividend profile are shaping sentiment around the stock. A fundamental review from GuruFocus on September 17, 2026, pointed out that Merck & Co.'s share price around USD 147 implied a premium of more than 20 percent to its GF Value estimate, while also discussing the sustainability of its dividend. A separate note from Yahoo Finance on September 16, 2026, emphasized Merck & Co.'s efforts to build a broader oncology and vaccines portfolio beyond its Keytruda franchise, which has helped keep the shares trading close to recent highs.

Today’s drivers and events

Looking ahead to today, Merck & Co. does not have a widely reported scheduled earnings release or annual meeting falling on September 18, 2026, but investor focus remains on developments around its oncology pipeline and dividend policy after the recent valuation debate highlighted by GuruFocus. Broader market conditions may also influence Merck & Co. stock today, as major US indices recently advanced on easing bond yields and firmer risk appetite, according to a US market report from Sharecast, which listed Merck & Co. among the healthcare names gaining in the latest session. Against this backdrop, Merck & Co. stock heads into the open after a session in which it not only added 1.56 percent but also continued to trade near recent highs, leaving investors attentive to any company or sector news that could influence the next move.

Disclaimer...

en | US58933Y1055 | MERCK & CO. | boerse | 70122568 | bgmi